Enanta Pharma (ENTA) Tops Q4 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2015
November 23, 2015 4:01 PM ESTConference Call and Webcast Today at 4:30 p.m. ET
Royalty revenue of $14.4 million in fourth quarter brings fiscal year total to $34.1 million AbbVies phase 3 trial begun for next-generation HCV treatment containing Enantas protease inhibitor ABT-493 Enantas cyclophilin inhibitor candidate EDP-494 expected to enter the clinic in the first calendar quarter of 2016 Cash and marketable securities totaled $209 million at September 30, 2015WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc., (NASDAQ:... More
